Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute talks about exciting new developments which will allow oncologists to test patients' lung tumors without invasive biopsies. February 2014.

[powerpress]

Dr. Charles Rudin of Memorial Sloan Kettering on how PARP inhibitors may benefit patients with small cell lung cancer. February 2014.

[powerpress]

Dr. Charles Rudin of Memorial Sloan Kettering discusses immune therapies that show promise in fighting lung cancer. February 2014.

[powerpress]

Dr. Heather Wakelee of Stanford University Medical Center discusses whether or not cabozantinib - a drug already approved for thyroid cancer - can help patients with lung cancer. February 2014.

[powerpress]

Dr. Edward Garon discusses what researchers are learning about MK-3475, an immune therapy treatment currently in clinical trial. February 2014. 

[powerpress]

Dr. Edward Garon warns that it is still too early to compare which immune therapies will be more effective in treating lung cancer.February 2014.

[powerpress]

Dr. Cathy Pietanza of Memorial Sloan Kettering discusses whether PARP treatments can be taken alone or if they must be taken with other drugs. February 2014.

[powerpress]

Why would an ALK lung cancer patient need a repeat biopsy? The doctors discuss the need for and frequency of repeat biopsies.

Several new treatments for ALK positive lung cancer patients are on the horizon. In this video, the doctors discuss them while patients in the audience share some of their experiences with side effects on various treatments.

[powerpress]

(IE/Firefox Users: If you have playback problems, please view on YouTube or try the "Download" button above. Get the latest QuickTime Player.)

New treatments for ALK rearrangements are on the horizon. In this video, the doctors discuss how they determine whether or not they change treatments for their patients once they begin to show progression while on Xalkori (crizotinib).

[powerpress]